Doxorubicin, liposomal
DefinitionThis section has been translated automatically.
Liposomal encapsulated doxorubicin.
IndicationThis section has been translated automatically.
AIDS-associated Kaposi sarcoma with low CD4 values (< 200 CD4 lymphocytes/ml) and extensive mucocutaneous and visceral involvement.
Pregnancy/nursing periodThis section has been translated automatically.
Do not use during pregnancy or breastfeeding (serious side effects on breastfed children)!
Dosage and method of useThis section has been translated automatically.
AIDS-associated Kaposi sarcomas: 20 mg/m2 KO in 250 ml 5% glucose for infusion i.v., every 2-3 weeks, for 2-3 months Continue treatment as long as necessary to maintain therapeutic success.
ContraindicationThis section has been translated automatically.
Do not use on AIDS-associated Kaposi sarcomas that can be successfully treated with local therapy or systemic interferon alpha therapy.
PreparationsThis section has been translated automatically.
Caelyx
Note(s)This section has been translated automatically.
The efficacy of pegylated liposomal doxorubicin for the treatment of mycosis fungoides has been described in several studies. The effectiveness of the therapy is still controversially discussed; in 2000, Wollina et al. reported a clinical response of 83% in a case report with 6 patients. Similarly good results were also published in subsequent studies. However, the significance of these studies is limited by the small number of subjects.
LiteratureThis section has been translated automatically.
- Wollina U et al (2000) Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42: 40-46